Lumida
/LFCR
⌘K
Lifecore Biomedical Inc

Lifecore Biomedical Inc

LFCR
$4.12USD↑+0.73%+0.03 today

MARKET CAP

156.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$4 – $4

52W RANGE

$4
$9

AI Summary

Stalk
TrimMedium

LFCR remains in a clear downtrend with sequential lower highs and a recent support failure below its intermediate moving averages. Despite extreme oversold readings, the medium-term bias stays bearish, favoring sell-side engagement only on relief into resistance zones. Short-term timing is unfavorable for further selling, suggesting deferred execution (Trim) rather than immediate action.

  • ↑Q3 revenue rose 26% YoY to $31.1M with 11 late-stage programs by 2028
  • ↑SG&A cut 40% YoY to $8.9M drove adjusted EBITDA to $8.6M in Q2
  • ↓FY 2025 net loss $34.5M; Q2 loss widened to $6.2M
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

LifeCore Biomedical Inc. (NASDAQ: LCBM) operates as a prominent Contract Development and Manufacturing Organization (CDMO), focusing on the production of high-quality injectable therapies, particularly hyaluronic acid products. The company aims to capitalize on the rising demand for injectables within the biopharmaceutical industry and is strategically positioned to leverage its technology-driven manufacturing capabilities amidst a growing market trend towards domestic production and regional manufacturing efficiencies.

Bull says

  • ↑Q3 revenue rose 26% YoY to $31.1M with 11 late-stage programs by 2028
  • ↑SG&A cut 40% YoY to $8.9M drove adjusted EBITDA to $8.6M in Q2
  • ↑Liquidity ~ $39M underpins 2026 revenue guidance of $120–125M
  • ↑Domestic injectables demand surging; 50% of pipeline is injectable
  • ↑Analysts forecast ~12% CAGR to 2029; strong relative-strength and positive revisions
  • ↑Resilient to rate shifts with strong momentum factors

Bear says

  • ↓FY 2025 net loss $34.5M; Q2 loss widened to $6.2M
  • ↓Leverage elevated, raising sustainability concerns
  • ↓Loss of key customer costs ~$7M annual revenue
  • ↓Commercial site transfers need 24–30 months, delaying cash flow
  • ↓Q2 revenue down 6.2% YoY to $34.2M; 2026 outlook cautious
  • ↓Weak profitability, negative earnings yield and high short interest

Investment themes with LFCR

Others↑ +0.32%

Miscellaneous or uncategorized companies

ATAI · SVIX · SVXY

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 08-16-2026bullish

Transcript signals

Bull points

  • investments that have been announced recently are only a tailwind for CDMOs in general and certainly for LifeCorps.
  • I've never seen this many or this amount or percentage of commercial site transfers become that you have the opportunity to compete on. So I look at it as only buoying the market from a CDMO perspective.
  • revenue for this seven-month stub period, or essentially the second half, of calendar year 25 are expected to be up significantly. So over 20% or about 14 million compared to an estimate of that same period of the prior year.

Bear points

  • For the three months ended September 30, 2025, the company recorded a net loss of $10 million and a loss of $0.29 per diluted share as compared to a net loss of $16.2 million and a loss of $0.53 per diluted share for the comparable prior period ended August 25, 2024.
  • the company recorded a net loss of $10 million and a loss of $0.29 per diluted share as compared to a net loss of $16.2 million and a loss of $0.53 per diluted share for the comparable prior period ended August 25, 2024.
Read full transcript analysis ›